CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Financial Statements and Exhibits
Item 9.01, the Page and the corrected Exhibit 3.1. This Amendment speaks as of the original filing date of the Original Filing and does not modify or update in any way disclosures made in the Original Filing other than to correct Exhibit 3.1.
Item 9.01. Financial Statements and Exhibits.
ChemoCentryx, Inc. Exhibit
EX-3.1 2 d721044dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CHEMOCENTRYX,…
To view the full exhibit click
About CHEMOCENTRYX, INC. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.